Effect of Thymalfasin in the Treatment of Chronic Obstructive Pulmonary Disease Complicated with Pulmonary Infection and Its Impact on Immune Function
ZHANG Yuhong
SONG Fenglian
CHEN Yong
Abstract：Objective To investigate the clinical efficacy of Thymalfasin combined with Cefoperazone and Sulbactam Sodium in the treatment of chronic obstructive pulmonary disease(COPD)complicated with pulmonary infection and its impact on immune function.Methods A retrospective analysis was performed on 84 patients with COPD complicated with pulmonary infection treated from March 2022 to March 2023,who were divided into the conventional group(n =39)and the combination group(n =45)according to the treatment plan.The conventional group was treated with Cefoperazone and Sulbactam Sodium,and the combination group was treated with Thymalfasin on the basis of conventional treatment.The clinical efficacy,inflam-matory response indicators,lung function indicators,blood gas analysis indicators and immune function of the two groups were compared.The occurrence of adverse reactions during treatment in the two groups was observed.Results The total effective rate of the combination group[93.33％(42/45)]was higher than that in the conventional group[76.92％(30/39)](P＜0.05).After treatment,serum procalcitonin,white blood cell count,C reactive protein,CD8+level and arterial partial pressure of carbon dioxide in the combination group were lower than those in the conventional group,and forced expiratory vol-ume in the first second(FEV1),ratio of FEV1 to forced vital capacity,partial pressure of arterial blood oxygen,and serum CD3+and CD4+levels were higher than those in conventional group(P＜0.05).There was no significant difference in the incidence of adverse reactions between the two groups(P＞0.05).Conclusion Thymalfasin combined with Cefoperazone and Sulbactam Sodium can effectively reduce the level of inflammatory response in COPD patients with pulmonary infection,improve lung function,and enhance immune function and clinical effect,with good safety.
Keywords：Pulmonary diseasechronic obstructivePulmonary infectionThymalfasinCefoperazone and Sulbactam SodiumSerum procalcitoninForced expiratory volume in the first secondPartial pressure of arterial oxygenCD8-positive T-lymphocytes
Publication Date：2023-10-20
Online Publishing Date：2025-08-15(First online date of this platform, not the publication date of the document)
Pages：4( 241-244 )